STAT

NOVEMBER 30, 2023

Food and Drug Administration approval for advanced ovarian cancer in 2022. Elahere is among a surging class of cancer medicines called antibody-drug conjugates, or ADCs, which are designed to deliver a targeted dose of chemotherapy directly to tumor cells while sparing healthy tissues.

Compounding 281

Compounding Compounding Pharmacies Chemotherapy 281

European Pharmaceutical Review

DECEMBER 19, 2022

The group adopted a positive opinion for Tremelimumab AstraZeneca (tremelimumab), to treat metastatic non-small cell lung cancer (NSCLC) in combination with Imfinzi (durvalumab) and platinum-based chemotherapy. EMA human medicines committee (CHMP) highlights, November 2022.

Generic Medicine 104

Generic Medicine Vaccines Chemotherapy 104

European Pharmaceutical Review

JULY 26, 2022

The committee has recommended that Rubraca (rucaparib camsylate) should no longer be used as third-line treatment for cancers of the ovary, fallopian tubes or peritoneum with a BRCA mutation in patients whose cancer has come back after at least two platinum-based chemotherapies and who cannot have further platinum-based therapy.

Vaccines 105

Vaccines Diabetes Chemotherapy 105

pharmaphorum

OCTOBER 27, 2022

Discussion was centred around ESMO 2022, where Dr Ray-Coquard presented collated data from a landmark five-year follow-up of the AstraZeneca/MSD PAOLA-1 phase 3 trial, the results from which suggested a clinically meaningful improvement in overall survival rates of certain patients with ovarian cancer.

Chemotherapy 94

Chemotherapy Hospitals 94

pharmaphorum

NOVEMBER 28, 2021

The three-year phase 2 trial will be carried out by researchers at Leeds University led by professor of clinical oncology and neuro-oncology Susan Short, and see if adding Sativex (nabiximols) to standard chemotherapy for recurrent glioblastoma can extend survival. Jazz acquired rights to Sativex when it completed its $7.2

Chemotherapy 136

Chemotherapy Hospitals 136

LifeProNow

JULY 14, 2023

The approval by China’s National Medical Products Administration (NMPA) is based on the results of the DESTINY-Breast04 Phase III trial , first presented at the American Society of Clinical Oncology 2022 Annual Meeting and published in The New England Journal of Medicine. months in those treated with chemotherapy.

Chemotherapy 130

Chemotherapy Hospitals 130

Pharmaceutical Technology

SEPTEMBER 13, 2022

Once patients become resistant to standard of care (SOC) endocrine-based therapies and CDK 4/6 inhibitors, the prognosis is poor, with treatment options limited to single-agent chemotherapies. Findings of the study, reported at the ESMO Congress 2022, demonstrated a 3.2-month months) versus physicians’ choice chemotherapy (11.2

Chemotherapy 64

Chemotherapy 64

Pharmaceutical Technology

MARCH 30, 2023

The European Commission (EC) has granted approval for Regeneron Pharmaceuticals’ Libtayo (cemiplimab), along with platinum-based chemotherapy, as the first-line treatment for PD-L1 expression positive advanced non-small cell lung cancer (NSCLC) in adult patients.

Chemotherapy 52

Chemotherapy Immunization Immunity 52

European Pharmaceutical Review

OCTOBER 1, 2022

A Phase III trial from Shanghai Henlius Biotech is the first study to suggest that the programmed cell death (PD) 1 receptor immune checkpoint inhibitor Hansizhuang (serplulimab) plus chemotherapy can markedly improve survival for extensive-stage small cell lung cancer (ES-SCLC) patients. The 24-month OS rate for both study groups was 43.1

Chemotherapy 98

Chemotherapy Immunization Immunity Hospitals 98

Pharmaceutical Technology

APRIL 21, 2023

The FDA previously accepted Daiichi Sankyo’s New Drug Application (NDA) for priority review as a potential treatment for TL3-ITD positive AML used alongside standard cytarabine and anthracycline induction and cytarabine consolidation chemotherapy in October 2022. reduction in the risk of death versus standard chemotherapy alone.

Chemotherapy 98

Chemotherapy 98

European Pharmaceutical Review

MARCH 21, 2023

This data led to the US approval for initial treatment of R/R LBCL in April 2022 and European Union approval in October 2022. Historical SOC involves platinum-based salvage combination chemoimmunotherapy regimen followed by high-dose therapy (HDT) and stem cell transplant (ASCT) in patients who respond to salvage chemotherapy.

Chemotherapy 145

Chemotherapy 145

Pharmaceutical Technology

SEPTEMBER 13, 2022

Presentations at the ESMO Congress 2022 have demonstrated the critical importance of therapy sequence, with astounding results for neoadjuvant ICI use in melanoma and microsatellite instability-high or mismatch repair deficient (MSI-H/dMMR) colorectal cancer (CRC). month progression-free survival (PFS) benefit over SOC chemotherapy.

Immunization 69

Immunization Immunity Chemotherapy 69

The Guardian - Pharmaceutical Industry

JANUARY 5, 2024

Pedro, five, was diagnosed with neuroblastoma; a fund has been set up so that his family can afford expensive chemotherapy drug Leading artists, Indigenous activists and politicians across Brazil are urging people to contribute to a fund to help the son of the slain Amazon activist Bruno Pereira , who has been diagnosed with a rare form of cancer.

Chemotherapy 93

Chemotherapy 93

European Pharmaceutical Review

DECEMBER 8, 2022

months for patients treated with Jemperli (dostarlimab) plus chemotherapy versus 6.7 months for those given pembrolizumab and chemotherapy. The GSK trial demonstrated an objective response rate (ORR) of 46 percent in patients treated with dostarlimab plus chemotherapy versus 37 percent for pembrolizumab with chemotherapy.

Chemotherapy 105

Chemotherapy 105

European Pharmaceutical Review

FEBRUARY 23, 2023

The approvals authorise the dual immunotherapy for first-line treatment in adults with advanced or unresectable hepatocellular carcinoma (HCC) and Imfinzi in combination with Imjudo and platinum-based chemotherapy for adults with metastatic (Stage IV) non-small cell lung cancer (NSCLC). percent for those treated with chemotherapy alone.

Chemotherapy 97

Chemotherapy 97

Pharmaceutical Technology

SEPTEMBER 14, 2022

This week, at the European Society of Medical Oncology (ESMO) Congress 2022 researchers presented encouraging updates on immunotherapies in the field of cervical cancer. months, combination treatment with Libtayo and chemotherapy significantly lowered the risk of death by 34% in the study cohort. Phase I/II Checkmate-358 trial.

Vaccines 59

Vaccines Chemotherapy Dosage 59

European Pharmaceutical Review

JANUARY 26, 2023

The approval is indicated for those who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy. The antibody drug conjugate (ADC) is the first HER2-directed therapy for HER2-low metastatic breast cancer.

Chemotherapy 97

Chemotherapy 97

Express Pharma

SEPTEMBER 23, 2024

AstraZeneca Pharma has received permission to import for sale and distribution of Durvalumab 120 mg/2.4 Around 15 per cent of patients with NSCLC in India have resectable disease representing a significant patient population.

Chemotherapy 104

Chemotherapy 104

ID Stewardship

DECEMBER 26, 2022

In this article we do a quick run down on IDstewardship for the end of 2022. . Article Posted 26 December 2022. 2022 has come and gone in what seems like a flash. TOP 3 NEW ARTICLES FROM 2022. EDITOR’S CHOICE: BEST ARTICLE OF 2022. Thank you to all of the contributors, collaborators, and interviewees in 2022!

Chemotherapy 52

Chemotherapy Hospitals 52

European Pharmaceutical Review

DECEMBER 7, 2022

In addition, A Phase III trial of Ivonescimab plus chemotherapy versus chemotherapy in epidermal growth factor receptor (EGFR) mutated advanced non-squamous NSCLC that failed in prior epidermal growth factor receptor EGFR tyrosine kinase inhibitors (TKIs) therapy is ongoing. percent and a median progression-free survival (mPFS) of 8.2

Chemotherapy 98

Chemotherapy 98

Pharmaceutical Business Review

FEBRUARY 10, 2025

The injection is claimed to be the first and only approved in the UK and European Union (EU) for preventing cisplatin chemotherapy-induced ototoxicity (hearing loss) in individuals aged one month to under 18 years with non-metastatic, localised solid tumours. InOctober 2023, the product was approved in the UKunder the brand name Pedmarqsi.

Chemotherapy 52

Chemotherapy Compounding 52

pharmaphorum

AUGUST 10, 2020

The results of the CheckMate-743 trial showed that a combination of Opdivo (nivolumab) with low-dose Yervoy (ipilimumab) reduced the risk of death by 26% compared to platinum-based chemotherapy after 22 months of follow-up.

Chemotherapy 111

Chemotherapy 111

European Pharmaceutical Review

NOVEMBER 4, 2022

Despite advances with targeted and immuno-oncology therapies, chemotherapies remain a cornerstone of cancer treatment for many tumour types – a reflection of their significant anti?tumour While highly effective, taxanes also exhibit several of the typical limitations associated with systemic chemotherapies. tumour effects. References.

Chemotherapy 98

Chemotherapy Hospitals Packaging 98

European Pharmaceutical Review

NOVEMBER 19, 2024

.” In a Q&A with EPR last year, Hoppin and Ratio’s Director, President and Chief Scientific Officer, Dr John Babich, described that “there is great hope of this class of drug specifically to work in conjunction with immunotherapeutics, given the lack of toxicity of radiopharmaceuticals in general compared to most chemotherapies.”

Chemotherapy 52

Chemotherapy 52

European Pharmaceutical Review

DECEMBER 12, 2024

This authorisation of the antibody drug conjugate Elahere provides a much needed clinically meaningful option for women living with this type of ovarian cancer, whose disease returns because they develop resistance to platinum-based chemotherapy regimens. Plymouth Meeting, PA: National Comprehensive Cancer Network 2022. 2022; 32(6).

Chemotherapy 98

Chemotherapy 98

European Pharmaceutical Review

MARCH 21, 2023

AstraZeneca and MSD’s treatment is indicated for adults with metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated. This analysis was presented at the 2022 ESMO Virtual Plenary Session in March 2022.

Chemotherapy 98

Chemotherapy Hospitals 98

pharmaphorum

SEPTEMBER 13, 2022

While they may not have known it at the time, through their work Ehrlich and Metschnikow formed the cornerstone of modern immunology, including chemoreceptor and chemotherapy concepts that revolutionised blood cancer treatment over the following century. 1942 – Chemotherapy moves from trenches to treatment .

Chemotherapy 98

Chemotherapy Immunization Immunity Documentation 98

European Pharmaceutical Review

AUGUST 12, 2022

The highest ORR was observed in patients with high levels of MET who were not treated with prior chemotherapy (52 percent). The results were shared at the International Association for the Study of Lung Cancer 2022 World Conference on Lung Cancer in Vienna, Austria.

Chemotherapy 98

Chemotherapy 98

pharmaphorum

JANUARY 27, 2023

Evusheld (tixagevimab and cilgavimab) was cleared by the FDA towards the end of 2021, becoming the first antibody to be authorised for prevention of COVID-19 infection, and it rapidly found use among people with compromised immune systems, such as cancer chemotherapy and organ-transplant patients.

Chemotherapy 135

Chemotherapy Immunization Immunity Vaccines 135

European Pharmaceutical Review

JUNE 5, 2024

These long-term results build on data first presented at the 2022 ASCO Annual Meeting and published in The New England Journal of Medicine. The updated analysis for the biologic Jemperli were presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (abstract LBA3512).

Chemotherapy 98

Chemotherapy 98

European Pharmaceutical Review

JANUARY 18, 2023

We launched ‘ An Accord for a Healthier World’ [in May 2022] to help reduce the glaring health equity gap that exists in our world. The medicines now on offer include chemotherapies and oral cancer treatments. The expansion now includes off-patent products, bringing the total offering from 23 to around 500 products.

Vaccines 98

Vaccines Chemotherapy Communication 98

pharmaphorum

DECEMBER 22, 2022

AstraZeneca’s (AZ) Imfinzi (durvalumab) has been approved in the European Union (EU) as first-line treatment of adult patients with unresectable or metastatic biliary tract cancer (BTC) in combination with chemotherapy (gemcitabine plus cisplatin). with chemotherapy. Updated median overall survival (OS) was 12.9 months versus 11.3

Chemotherapy 64

Chemotherapy Pharmaceutical Companies Pharmaceutical Companies 64

European Pharmaceutical Review

DECEMBER 21, 2022

The EC’s approval follows the positive recommendation in the EU by the Committee for Medicinal Products for Human Use (CHMP) in November 2022. 0.81; p<0.0001). Current approvals of Lynparza.

Chemotherapy 110

Chemotherapy Hospitals 110

pharmaphorum

JANUARY 26, 2023

Yescarta is administered to the patient via a single intravenous infusion following the administration of a round of chemotherapy designed to accommodate the new cells and minimise the patient’s immune reaction to them. About 50% will ultimately relapse post-transplant.

Chemotherapy 96

Chemotherapy Immunization Immunity Hospitals 96

European Pharmaceutical Review

APRIL 3, 2023

The committee recommended granting a paediatric-use marketing authorisation (PUMA) for Pedmarqsi (sodium thiosulfate) for preventing ototoxicity induced by cisplatin chemotherapy. Cisplatin is a chemotherapy used to treat several types of cancer. Ototoxicity is the development of hearing or balance problems due to a medicine.

Vaccines 98

Vaccines Chemotherapy Generic Medicine Biosimilars 98

Pharmaceutical Technology

MAY 10, 2023

The approval was given to TYVYT (sintilimab injection) plus bevacizumab and chemotherapy (pemetrexed and cisplatin). Major secondary endpoints of objective response rate and duration of response were also found to be improved when patients were treated with sintilimab plus bevacizumab plus chemotherapy, in comparison with chemotherapy alone.

Chemotherapy 52

Chemotherapy 52

European Pharmaceutical Review

NOVEMBER 6, 2023

In addition to being indicated in those with progressive disease, Mirati Therapeutics shared that the treatment is also authorised for patients with, or intolerance to, platinum-based chemotherapy and/or anti-PD-1/PD-L1 immunotherapy.

Chemotherapy 98

Chemotherapy Hospitals 98